Answers are grounded in this paper and cite their sources.
Aim: Breast cancer is a heterogeneous disease. This study investigated the pretreatment prognostic significance of a new inflammatory index in hormone receptor positive (HR+) and human epidermal growth factor negative (HER2-) breast cancer patients. Methods: We retrospectively analyzed 80 patients diagnosed with HR+ and HER2-breast cancer between January 2014 and December 2018. We calculated prognostic inflammatory index (PII) = mean platelet volume (MPV) neutrophil/lymphocyte. PII cut off was the best-predicted value by receiver operating characteristic (ROC) curve analysis. We used the Kaplan-Meier method to determine disease-free survival (DFS). We used the log-rank test to compare the DFS rates between the two patient groups. We performed a multivariate analysis by performing Cox regression analysis with prognostic factors defined in univariate analysis. Results: The median follow-up period was 38 (19-66) months. The 5-year survival was 91.3%. The 5-year DFS was 87.9%. The optimal cut-off value of MPV neutrophil/lymphocyte ratio was determined as 22 by ROC curve analysis [area under the curve, AUC 735, HR % CI (confidence interval) 0.561-0.909, sensitivity 72.7%, specificity 70.4%]. The number of patients with PII 22 was 60, and the number of patients with PII >22 was 32. DFS was worse in the high PII group than in the low PII group (p = 0.001). Multivariate analysis revealed PII as an independent prognostic factor (p = 0.016). Discussion: In this study, we detected elevated MPV neutrophil/lymphocyte ratio as an independent poor prognostic factor in operated HR+ and HER2-breast cancer patients. Prospective studies are needed to determine the prognostic significance of this index.
No takes yet. Share an insight, caveat, or question.
Şahinli et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: